Green Zebras SA
8.75
PLN
+0.05
(+0.57%)
Green Zebras SA
GPW:GRZ
(Warsaw Stock Exchange)
Recent
price
8.75
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Green Zebras S.A. is a Poland-based biotechnology and contract processing company specializing in botanical extraction, natural active ingredient formulations, and veterinary therapeutic development. Founded in 2020 and headquartered in Wrocław, Poland, the company operates as a publicly traded entity listed on the NewConnect alternative market of the Warsaw Stock Exchange under the ticker GPW:GRZ. The company operates across two core business segments: Botanical Extraction and Processing, and Veterinary Biotechnology. In its botanical processing division, Green Zebras S.A. manufactures, formulates, and supplies over 40 natural extracts derived from herbs, industrial hemp, hops, adaptogenic mushrooms, fruits, vegetables, and spices; produces standardized extracts in multiple delivery formats, including liquid solutions, viscous concentrates, and freeze-dried lyophilized powders; provides comprehensive contract development and manufacturing organization and private-label processing services; executes low-temperature cryogenic extraction, ethanol solvent extraction, vacuum concentration, and lyophilization; and delivers formulation design, product prototyping, regulatory compliance support, and analytical testing for end applications in dietary supplements, functional food and beverages, cosmetics, and veterinary care products. In its veterinary biotechnology division, the company develops specialized therapeutics and diagnostic solutions for companion animals, including dogs, cats, and horses, focusing on target indications in veterinary oncology, cardiology, nephrology, and geriatrics. Green Zebras S.A. operates primarily as a business-to-business supplier and contract partner serving corporate clients across the nutraceutical, cosmeceutical, and animal health sectors in Poland and broader European markets. The company utilizes a virtual biotech operating model for its clinical and pharmaceutical research, outsourcing specialized laboratory execution to scientific institutions and clinical research organizations while managing pipeline intellectual property and commercial licensing internally. In recent corporate developments, Green Zebras S.A. completed its public debut on the Warsaw Stock Exchange NewConnect market in September 2024. Following its listing, the company initiated a strategic transition under its 2026-2030 corporate plan to expand from contract extraction services into high-value veterinary biotechnology and oncology. In September 2026, Green Zebras S.A. signed a strategic cooperation agreement and letter of intent with Wrocław Medical University to collaborate on the development and commercialization of the GMTX technology, an innovative glucose-methotrexate conjugate oncology therapy for companion animals, securing exclusive negotiation rights and a right of first refusal for future intellectual property discoveries. This expansion followed the company's organizational evolution from its original formation as Laborathorium sp. z o.o. in 2020, its rebranding to Green Zebras in 2021, and its formal transformation into a joint-stock company in December 2022.